Hansen Medical Announces Employment Inducement Awards
28 5월 2014 - 5:05AM
Marketwired
Hansen Medical Announces Employment Inducement Awards
MOUNTAIN VIEW, CA--(Marketwired - May 27, 2014) - Hansen
Medical, Inc. (NASDAQ: HNSN) announced today the grant of a stock
option to its newly appointed president and chief executive
officer. Cary Vance, who joined the Company as its President and
Chief Executive Officer on May 23, 2014 (the "Start Date"), was
granted an option to purchase 851,915 shares of the Company's
Common Stock, 25% of which will vest after 12 months of continuous
employment, and the balance of which will vest in 36 successive
equal monthly installments thereafter (the "Inducement Option").
The Company will also grant Mr. Vance a restricted stock unit award
equal to 238,439 shares of the Company's Common Stock, 25% of which
will vest on June 1, 2015 and an additional 6.25% of which will
vest on March 1st, June 1st, September 1st and December 1st of each
year thereafter (provided Mr. Vance remains in continuous
employment through each such vesting date) (the "Inducement RSUs")
and a performance stock unit award of up to 238,439 shares of the
Company's Common Stock that will vest based on fiscal year 2015
revenue and Mr. Vance's continued employment through applicable
vesting dates (the "Inducement PSUs," and together with the
Inducement Option and the Inducement RSUs, the "Inducement
Awards"). The Inducement Awards are being granted outside of the
Company's 2006 Equity Incentive Plan, but will generally be subject
to the same terms and conditions as apply to awards granted under
that plan. The Company's Board of Directors (including a majority
of the Company's Independent Directors) approved the Inducement
Awards in reliance on the employment inducement exception to the
NASDAQ rules that require shareholder approval of equity-based
incentive plans and awards. The NASDAQ rules require the public
announcement of such inducement awards.
The Inducement Option was granted on the Start Date and will
expire 10 years from the Start Date. The per share exercise price
for the Inducement Option is $1.40, which was the closing sales
price of the Company's Common Stock on the Start Date as reported
by NASDAQ. 158,995 of the of the Inducement PSUs will vest based on
the achievement of both the Company's fiscal year 2015 revenue
target (the "Performance Condition") and Mr. Vance's continued
employment through applicable vesting dates. Mr. Vance will be
eligible to vest in the additional Inducement PSUs if the
Performance Condition is exceeded and Mr. Vance's employment
continues through the applicable vesting dates.
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is a
global leader in Intravascular Robotics, developing products and
technology designed to enable the accurate positioning,
manipulation and control of catheters and catheter-based
technologies. The Company's Magellan™ Robotic System, 9Fr Magellan™
Robotic Catheter, Magellan™ 6Fr Robotic Catheter, and related
accessories are intended to facilitate navigation to anatomical
targets in the peripheral vasculature and subsequently provide a
conduit for manual placement of therapeutic devices. The Magellan
9Fr Robotic Catheter has undergone both CE marking and 510(k)
clearance and is commercially available in the European Union, and
the U.S. The Magellan 6Fr Robotic Catheter has undergone 510(k)
clearance in the U.S. and is in limited release for the next
several months in anticipation of more wide-scale commercially
availability later in 2014. In the European Union, the Company's
Sensei® X Robotic Catheter System and Artisan® and Artisan Extend®
Control Catheters are cleared for use during electrophysiology (EP)
procedures, such as guiding catheters in the treatment of atrial
fibrillation (AF), and the Lynx® Robotic Ablation Catheter is
cleared for the treatment of AF. This robotic catheter system is
compatible with fluoroscopy, ultrasound, 3D surface map and patient
electrocardiogram data. In the U.S., the Company's Sensei X Robotic
Catheter System and Artisan and Artisan Extend Control Catheters
are cleared by the U.S. Food and Drug Administration for
manipulation and control of certain mapping catheters in EP
procedures. In the U.S., the Sensei X Robotic Catheter System is
not approved for use in guiding ablation procedures; this use
remains experimental. The U.S. product labeling therefore provides
that the safety and effectiveness of the Sensei X Robotic Catheter
System and Artisan and Artisan Extend Control Catheter for use with
cardiac ablation catheters in the treatment of cardiac arrhythmias,
including AF, have not been established. Additional information can
be found at www.hansenmedical.com.
Investor Contacts: Peter J. Mariani Chief Financial Officer
Hansen Medical, Inc. 650.404.5800 Westwicke Partners, LLC. Mark
Klausner or Mike Piccinino, CFA 443.213.0500
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024